Metriport Pulls In $26 Million to Speed Patient Record Retrieval

Metriport, a startup whose software helps doctors retrieve patient medical records from disparate health systems, raised $26 million in a Series A round led by Matrix, with participation from ARTIS and Y Combinator.

Metriport, a startup building software that helps clinicians pull a patient's medical records out of the many systems those records happen to sit in, has raised $26 million in a Series A round. Matrix led the financing, with additional participation from ARTIS and Y Combinator, according to Endpoints News, which reported the raise exclusively.

The company sits in a corner of health technology that is unglamorous and stubbornly unsolved: getting a complete picture of a patient's history in front of the person treating them. A single adult in the United States can accumulate records across a primary care practice, two or three hospital systems, an urgent care chain, a handful of specialists, an imaging center and a pharmacy benefit manager — each running different software, each with its own rules about what leaves the building and how.

Why record retrieval is still a business worth funding

Interoperability has been a stated policy goal in American healthcare for well over a decade, and it has been legislated at repeatedly. The technical standards exist. What has not existed, in practice, is a reliable way for a clinician or a downstream application to make one request and receive a usable, structured history back — without a fax machine, a release-of-information vendor, or a staff member on hold.

That gap is what startups in this niche sell against. The pitch is straightforward: rather than each provider group, digital health app, care management vendor or life sciences team building its own connections into national data exchange networks and individual electronic health record systems, they call an application programming interface — a standardized software connection point — and get records back.

The buyers are broader than the word "doctors" suggests. Anyone who needs a patient's longitudinal history has the same problem: value-based care organizations calculating risk, digital health companies onboarding new members, insurers doing chart review, and clinical research teams screening for eligibility. Each of those constituencies has its own compliance overhead, which is part of why the plumbing has proved so hard to commoditize.

What the investor group signals

Matrix leading a Series A places Metriport in the category of infrastructure bets rather than clinical-outcomes bets — the kind of company judged on developer adoption, request volume and gross margin rather than on trial readouts. ARTIS joining alongside adds a second institutional check. Y Combinator's presence indicates Metriport came through the accelerator, and the fact that it is still on the cap table at Series A is the usual pattern for a YC company that has found early traction.

A $26 million Series A is a substantial round for a company selling developer infrastructure into healthcare. Rounds of that size at that stage typically fund three things: engineering headcount to widen network coverage and improve data quality, a go-to-market team to move from self-serve developer adoption into enterprise contracts, and the security and compliance apparatus that large health systems and payers demand before signing.

Neither the size of the company's customer base nor its revenue was disclosed, and no valuation was attached to the round in the reporting.

The competitive shape of the market

Metriport is not entering an empty field. Health data exchange has attracted well-capitalized private companies, incumbent EHR vendors that treat data access as a feature of their own platforms, and the national exchange frameworks themselves. The federal push toward a common set of exchange rules has lowered one barrier — participants have a defined way to ask each other for records — while raising the bar on what a vendor has to do to be useful. If everyone can technically reach the network, the differentiation moves to coverage breadth, latency, and how clean the returned data is once it arrives.

Data quality is the part customers complain about most. Raw records retrieved from a national network arrive as documents of wildly varying structure, frequently duplicated across sources, sometimes contradictory. Turning that into something a clinician can scan in thirty seconds, or an algorithm can compute on, is where the engineering work sits.

The AI cycle has sharpened demand here as well. Clinical language models and ambient documentation tools are only as good as the patient context they are fed, and that context has to come from somewhere. Every company building a clinical AI product faces the same choice: build record retrieval itself, or buy it. That dynamic has made data-access infrastructure a more attractive place to deploy venture capital than it was a few years ago.

The financing backdrop

The round lands in a private market that has been selective with health technology. Capital has concentrated in companies that can point to revenue and a defensible technical position, rather than in broad consumer health plays. Infrastructure businesses — ones that sell into other companies and get paid per transaction or per seat — have generally fared better in that environment than businesses that must acquire patients directly.

Public markets, for their part, closed the week soft. The S&P 500 tracker SPY finished at $769.39, down 0.22% on the day from a prior close of $771.10, as of the last trade on Friday, 28 August 2026. The Nasdaq 100 tracker QQQ ended at $716.47, off 0.64%, while the Dow tracker DIA was essentially flat at $535.10. Private rounds are not priced off daily index moves, but the tone of the growth-equity market — and the eventual exit environment for a company like Metriport — tracks the same broad appetite for risk.

What to watch from here

Three things will tell whether the $26 million was well placed. First, network coverage: how much of a typical American patient's history Metriport can actually return, and how quickly. Second, customer mix — whether the company converts developer users into large, multi-year enterprise agreements with health systems and payers, which is where the durable revenue lives. Third, regulatory drift: information-blocking enforcement and any changes to the national exchange rules can either widen the moat for a specialist vendor or shrink it, depending on how much of the work the framework itself absorbs.

For now, the company has capital, a lead investor with an infrastructure thesis, and a problem that has resisted solution long enough to be worth solving.

Key facts

• Amount raised: $26 million Series A
• Lead investor: Matrix
• Other backers: ARTIS and Y Combinator
• Market backdrop: SPY closed at $769.39, -0.22%, as of 28 Aug 2026 20:00 GMT

Frequently asked questions

How much did Metriport raise and who led the round?

Metriport raised $26 million in a Series A financing led by Matrix. ARTIS and Y Combinator also participated in the round. The company builds software that makes it easier for doctors to retrieve patient medical records. No valuation was disclosed alongside the raise, and the company's revenue and customer count were not made public.

What problem does Metriport's product address?

A single patient's medical history is typically scattered across hospitals, clinics, specialists, imaging centers and pharmacies, each using different software. Metriport provides software that lets a doctor or an application make one request and retrieve records from those disparate sources, rather than relying on faxes, phone calls or manual release-of-information processes.

Is Metriport a publicly traded company?

No. Metriport is a privately held startup and has no listed shares. A Series A is an early institutional financing round, typically raised before a company approaches profitability or a public listing. Investors in the round — Matrix, ARTIS and Y Combinator — hold private equity stakes rather than exchange-traded securities.

What is an API and why does it matter here?

An application programming interface is a standardized software connection point that lets one program request data from another. For health records, an API means a digital health company or clinic does not have to build custom links to every hospital system and exchange network — it makes one call and receives records back in a consistent format.

Who buys health data retrieval software?

Beyond individual physician practices, buyers include value-based care organizations calculating patient risk, digital health companies onboarding members, insurers conducting chart review, and clinical research teams screening trial candidates. Increasingly, clinical AI developers also need patient context, which has broadened demand for record-retrieval infrastructure.

What were markets doing when the funding was reported?

As of the last trade on Friday, 28 August 2026 at 20:00 GMT, the S&P 500 tracker SPY closed at $769.39, down 0.22% from a prior close of $771.10. The Nasdaq 100 tracker QQQ ended at $716.47, down 0.64%, and the Dow tracker DIA closed at $535.10, essentially unchanged.

Sources

• Metriport raises $26M to help doctors retrieve patient data — Endpoints News

Photo: SHVETS production · Pexels Licence — source